Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.05B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$404M |
| 3 |
AstraZeneca
AZN
|
+$342M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$288M |
| 5 |
Willis Towers Watson
WTW
|
+$227M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icahn Enterprises
IEP
|
+$641M |
| 2 |
Microsoft
MSFT
|
+$549M |
| 3 |
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$538M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$294M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$275M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.22% |
| 2 | Financials | 7.52% |
| 3 | Healthcare | 6.46% |
| 4 | Consumer Discretionary | 6.41% |
| 5 | Communication Services | 4.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Zentalis Pharmaceuticals
ZNTL
$332M
| $4.07M | ﹤0.01% |
76,565
-5,807
| -7% | -$311K |
|
2052
Arbor Realty Trust
ABR
$977M
| $4.07M | ﹤0.01% |
228,154
+139,775
| +158% | +$2.46M |
|
2053
3D Systems Corp
DDD
$405M
| $4.06M | ﹤0.01% |
101,651
+11,166
| +12% | +$295K |
|
2054
PUT
Freshpet
FRPT
$3.04B
| $4.06M | ﹤0.01% |
+24,900
| New | +$4.25M |
|
|
PPBI
2055
DELISTED
Pacific Premier Bancorp
PPBI
| $4.06M | ﹤0.01% |
95,938
+25,970
| +37% | +$1.15M |
|
2056
Allot
ALLT
$362M
| $4.05M | ﹤0.01% |
204,429
+38,539
| +23% | +$710K |
|
2057
Kymera Therapeutics
KYMR
$8.66B
| $4.05M | ﹤0.01% |
83,465
+19,780
| +31% | +$859K |
|
2058
Personalis
PSNL
$1.25B
| $4.05M | ﹤0.01% |
159,969
+34,494
| +27% | +$789K |
|
|
NATI
2059
DELISTED
National Instruments Corp
NATI
| $4.04M | ﹤0.01% |
95,646
+3,103
| +3% | +$131K |
|
2060
QuidelOrtho
QDEL
$1.13B
| $4.04M | ﹤0.01% |
31,562
+4,764
| +18% | +$561K |
|
2061
Imperial Oil
IMO
$62.3B
| $4.04M | ﹤0.01% |
132,534
+28,899
| +28% | +$871K |
|
2062
AMC Global Media
AMCX
$450M
| $4.04M | ﹤0.01% |
60,476
-22,309
| -27% | -$1.23M |
|
2063
Valmont Industries
VMI
$8.86B
| $4.04M | ﹤0.01% |
17,101
+38
| +0.2% | +$9.2K |
|
2064
Matsons
MATX
$6.11B
| $4.03M | ﹤0.01% |
63,011
+5,916
| +10% | +$386K |
|
2065
PUT
NRG Energy
NRG
$26.2B
| $4.03M | ﹤0.01% |
100,000
-225,000
| -69% | -$8.15M |
|
|
CCV
2066
CALL
DELISTED
Churchill Capital Corp V
CCV
| $4.03M | ﹤0.01% |
+400,000
| New | +$4M |
|
|
CCV
2067
DELISTED
Churchill Capital Corp V
CCV
| $4.03M | ﹤0.01% |
+399,980
| New | +$4M |
|
|
PRO
2068
DELISTED
PROS Holdings
PRO
| $4.03M | ﹤0.01% |
88,358
-6,722
| -7% | -$297K |
|
2069
Abercrombie & Fitch
ANF
$4.55B
| $4.03M | ﹤0.01% |
86,705
+32,401
| +60% | +$1.31M |
|
2070
CALL
Aflac
AFL
$65.5B
| $4.03M | ﹤0.01% |
+75,000
| New | +$4.09M |
|
2071
Celldex Therapeutics
CLDX
$2.94B
| $4.02M | ﹤0.01% |
120,254
-53,024
| -31% | -$1.46M |
|
2072
First Trust Capital Strength ETF
FTCS
$8.05B
| $4.02M | ﹤0.01% |
53,195
+1,848
| +4% | +$137K |
|
2073
Idacorp
IDA
$8B
| $4.02M | ﹤0.01% |
41,221
-938
| -2% | -$94K |
|
|
MYOV
2074
DELISTED
Myovant Sciences Ltd.
MYOV
| $4.02M | ﹤0.01% |
176,491
+174,871
| +10,795% | +$3.68M |
|
2075
Karyopharm Therapeutics
KPTI
$155M
| $4.01M | ﹤0.01% |
25,935
+3,531
| +16% | +$512K |
|
Similar funds
Citigroup's Q2 2021 Portfolio in Review
As of Q2 2021, Citigroup held 6,654 positions worth $166B, up 7.5% from $155B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Citigroup's Q2 2021 filing shows 397 new, 2,681 increased, 2,205 reduced and 444 closed positions. Its largest new stake was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 7,128,000 shares worth $71.4M. The largest sale was Icahn Enterprises, an estimated $641M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Financials and Healthcare.
- Citigroup's largest Q2 2021 buy was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 7,128,000 shares worth $71.4M.
- Citigroup added most to State Street SPDR S&P 500 ETF Trust in Q2 2021, an estimated $2.05B increase.
- Citigroup's biggest Q2 2021 reduction was Icahn Enterprises, cutting an estimated $641M.
- Citigroup fully exited RealPage, Inc. in Q2 2021, selling an estimated $226M.
- Citigroup's ten largest holdings make up 20% of its $166B portfolio in Q2 2021.
- Citigroup opened 397 new positions and closed 444 in Q2 2021.
- Citigroup's portfolio value rose 7.5% quarter-over-quarter to $166B.
Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.